These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11167671)

  • 1. Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
    Jones K; Hoggard PG; Khoo S; Maher B; Back DJ
    Br J Clin Pharmacol; 2001 Jan; 51(1):99-102. PubMed ID: 11167671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular accumulation of human immunodeficiency virus protease inhibitors.
    Khoo SH; Hoggard PG; Williams I; Meaden ER; Newton P; Wilkins EG; Smith A; Tjia JF; Lloyd J; Jones K; Beeching N; Carey P; Peters B; Back DJ
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3228-35. PubMed ID: 12234849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
    Boffito M; Hoggard PG; Reynolds HE; Bonora S; Meaden ER; Sinicco A; Di Perri G; Back DJ
    Br J Clin Pharmacol; 2002 Sep; 54(3):262-8. PubMed ID: 12236846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
    Jones K; Hoggard PG; Sales SD; Khoo S; Davey R; Back DJ
    AIDS; 2001 Apr; 15(6):675-81. PubMed ID: 11371681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
    Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.
    King JR; Gerber JG; Fletcher CV; Bushman L; Acosta EP
    AIDS; 2005 Jul; 19(10):1059-63. PubMed ID: 15958837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors.
    Zhang XQ; Schooley RT; Gerber JG
    J Infect Dis; 1999 Dec; 180(6):1833-7. PubMed ID: 10558938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells.
    Armbruster C; Vorbach H; Steindl F; El Menyawi I
    J Antimicrob Chemother; 2001 Apr; 47(4):487-90. PubMed ID: 11266428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
    Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
    Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.
    Diker B; Janneh O; van Heeswijk RP; Copeland KF
    Drug Metab Lett; 2010 Dec; 4(4):241-5. PubMed ID: 20690898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
    Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
    AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
    J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
    Buss N; Snell P; Bock J; Hsu A; Jorga K
    Br J Clin Pharmacol; 2001 Sep; 52(3):255-64. PubMed ID: 11560557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
    Chi J; Jayewardene AL; Stone JA; Motoya T; Aweeka FT
    J Pharm Biomed Anal; 2002 Oct; 30(3):675-84. PubMed ID: 12367693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
    Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
    Colombo S; Buclin T; Décosterd LA; Telenti A; Furrer H; Lee BL; Biollaz J; Eap CB;
    Clin Pharmacol Ther; 2006 Oct; 80(4):307-18. PubMed ID: 17015049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
    Eagling VA; Back DJ; Barry MG
    Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
    Chai H; Yang H; Yan S; Li M; Lin PH; Lumsden AB; Yao Q; Chen C
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):12-9. PubMed ID: 16123675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.